Cargando…
Small airway dysfunction and poor asthma control: a dangerous liaison
Asthma is a common chronic condition, affecting approximately 339 million people worldwide. The main goal of the current asthma treatment guidelines is to achieve clinical control, encompassing both the patient symptoms and limitations and the future risk of adverse asthma outcomes. Despite randomiz...
Autores principales: | Cottini, Marcello, Licini, Anita, Lombardi, Carlo, Bagnasco, Diego, Comberiati, Pasquale, Berti, Alvise |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8164746/ https://www.ncbi.nlm.nih.gov/pubmed/34051816 http://dx.doi.org/10.1186/s12948-021-00147-8 |
Ejemplares similares
-
Asthma and COVID-19: a dangerous liaison?
por: Lombardi, Carlo, et al.
Publicado: (2021) -
Monoclonal antibodies targeting small airways: a new perspective for biological therapies in severe asthma
por: Lombardi, Carlo, et al.
Publicado: (2022) -
Small Airways: The “Silent Zone” of 2021 GINA Report?
por: Cottini, Marcello, et al.
Publicado: (2022) -
Small airway dysfunction and bronchial asthma control : the state of the art
por: Cottini, Marcello, et al.
Publicado: (2015) -
Using the 6-min walk test to assess the clinical response to mepolizumab and conventional therapy in severe eosinophilic asthma
por: Lombardi, Carlo, et al.
Publicado: (2023)